<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pbio</journal-id><journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id><journal-id journal-id-type="pmc">plosbiol</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Biology</journal-title></journal-title-group><issn pub-type="epub">1545-7885</issn><issn pub-type="ppub">1544-9173</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pbio.0000059</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Oncology</subject>
          <subject>Cell Biology</subject>
          <subject>Genetics and Genomics</subject>
          <subject>Molecular Biology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Mus (mouse)</subject>
        </subj-group>
      </article-categories><title-group><article-title>Pten Dose Dictates Cancer Progression in the Prostate</article-title><alt-title alt-title-type="running-head">Pten in Prostate Cancer Suppression</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Trotman</surname>
            <given-names>Lloyd C</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Niki</surname>
            <given-names>Masaru</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dotan</surname>
            <given-names>Zohar A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Koutcher</surname>
            <given-names>Jason A</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Di Cristofano</surname>
            <given-names>Antonio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Xiao</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Khoo</surname>
            <given-names>Alan S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Roy-Burman</surname>
            <given-names>Pradip</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Greenberg</surname>
            <given-names>Norman M</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dyke</surname>
            <given-names>Terry Van</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cordon-Cardo</surname>
            <given-names>Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Pandolfi</surname>
            <given-names> Pier Paolo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">
        <label>1</label>
        
        <addr-line>Molecular Biology Program, Memorial Sloan–Kettering Cancer Center,
          Sloan–Kettering Institute, New York, New York, United States of America</addr-line>
        
      </aff><aff id="aff2">
        <label>2</label>
        
        <addr-line>Department of Pathology, Memorial Sloan–Kettering Cancer Center,
          Sloan–Kettering Institute, New York, New York, United States of America</addr-line>
        
      </aff><aff id="aff3">
        <label>3</label>
        
        <addr-line>Department of Radiology, Memorial Sloan–Kettering Cancer Center,
          Sloan–Kettering Institute, New York, New York, United States of America</addr-line>
        
      </aff><aff id="aff4">
        <label>4</label>
        
        <addr-line>Department of Biochemistry and Biophysics, University of North Carolina at
          Chapel Hill, Chapel Hill, North Carolina, United States of America</addr-line>
        
      </aff><aff id="aff5">
        <label>5</label>
        
        <addr-line>Departments of Pathology and Biochemistry and Molecular Biology, Keck School of
          Medicine, University of Southern California, Los Angeles, California, United States of America</addr-line>
        
      </aff><aff id="aff6">
        <label>6</label>
        
        <addr-line>Departments of Molecular and Cellular Biology and Urology, Baylor College of
          Medicine, Houston, Texas, United States of America</addr-line>
        
      </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Nicholas Hastie</surname>
          </name>
          <role>Academic Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Medical Research Council Human Genetics Unit, Western General Hospital</aff><author-notes>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">p-pandolfi@ski.mskcc.org</email></corresp>
        <fn fn-type="con" id="n2">
          <p> LCT, MN, ZAD, JAK, AD, AX, TVD, CC-C, and PPP
            conceived and designed the experiments. LCT, MN, ZAD, JAK, AD, and AX performed the
            experiments. LCT, MN, ZAD, JAK, AD, AX, ASBK, TVD, CC-C, and PPP analyzed the data.
            PR-B, NMG, TVD, and PPP contributed reagents/materials/analysis tools. LCT, MN, ZAD, and
            PPP wrote the paper.</p>
        </fn>
      <fn fn-type="conflict" id="n1">
        <p> The authors have declared that no conflicts of
          interest exist.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>12</month>
        <year>2003</year>
      </pub-date><pub-date pub-type="epub">
        <day>27</day>
        <month>10</month>
        <year>2003</year>
      </pub-date><volume>1</volume><issue>3</issue><elocation-id>e59</elocation-id><history>
        <date date-type="received">
          <day>2</day>
          <month>8</month>
          <year>2003</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>9</month>
          <year>2003</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2003</copyright-year><copyright-holder>Lee et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of
        the Public Library of Science Open-Access License, which permits unrestricted use,
        distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article page="e70" related-article-type="companion" vol="1" xlink:href="info:doi/10.1371/journal.pbio.0000070" xlink:title="synopsis" xlink:type="simple">
        <article-title>Dose of <italic>PTEN</italic> Gene Drives Progression of Prostate
        Cancer</article-title>
      </related-article><abstract>
        <p>Complete inactivation of the <italic>PTEN</italic> tumor suppressor gene is extremely
          common in advanced cancer, including prostate cancer (CaP). However, one
          <italic>PTEN</italic> allele is already lost in the vast majority of CaPs at presentation.
          To determine the consequence of PTEN dose variations on cancer progression, we have
          generated by homologous recombination a hypomorphic <italic>Pten</italic> mouse mutant
          series with decreasing Pten activity: <italic>Pten</italic><sup>hy/+</sup>
          &gt; <italic>Pten</italic><sup>+/−</sup> &gt;
            <italic>Pten</italic><sup>hy/−</sup> (mutants in which we have rescued the
          embryonic lethality due to complete <italic>Pten</italic> inactivation) &gt;
            <italic>Pten</italic> prostate conditional knockout (<italic>Pten</italic><sup>pc</sup>)
          mutants. In addition, we have generated and comparatively analyzed two distinct
            <italic>Pten</italic><sup>pc</sup> mutants in which <italic>Pten</italic> is inactivated
          focally or throughout the entire prostatic epithelium. We find that the extent of
            <italic>Pten</italic> inactivation dictate in an exquisite dose-dependent fashion CaP
          progression, its incidence, latency, and biology. The dose of Pten affects key downstream
          targets such as Akt, p27<sup>Kip1</sup>, mTOR, and FOXO3. Our results provide conclusive
          genetic support for the notion that <italic>PTEN</italic> is haploinsufficient in tumor
          suppression and that its dose is a key determinant in cancer progression.</p>
      </abstract><abstract abstract-type="toc">
        <p>Mice with progressively decreasing amounts of the tumor suppressor PTEN demonstrate that
          this gene affects -- in an exquisite dose-dependent fashion -- prostate tumor incidence
          and progression.</p>
      </abstract></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>The <italic>PTEN</italic> (phosphatase and tensin homolog deleted on chromosome 10) tumor
        suppressor gene is located on chromosome 10q23, a genomic region frequently lost in human
        cancers. Somatic deletions or mutations of this gene have been identified in a large
        fraction of tumors, frequently in prostate cancer (CaP), placing <italic>PTEN</italic> among
        the most commonly mutated tumor suppressor genes in human cancer (<xref ref-type="bibr" rid="pbio.0000059-Cantley1">Cantley and Neel 1999</xref>; <xref ref-type="bibr" rid="pbio.0000059-Di1">Di Cristofano and Pandolfi 2000</xref>).</p>
      <p>As dictated by Knudson's “two-hit” hypothesis <xref ref-type="bibr" rid="pbio.0000059-Knudson1">(Knudson 1971)</xref>, however, the analysis of cancer samples
        for mutations in <italic>PTEN</italic> has been performed searching for biallelic
        inactivation of the gene, which pointed at complete <italic>PTEN</italic> inactivation as a
        late event in cancer progression. The consequence of loss or mutation in one
        <italic>PTEN</italic> allele in carcinomas in situ or in primary cancers may have been
        underestimated. It could be postulated that if <italic>PTEN</italic> were to be
        haploinsufficient for some of its tumor-suppressive functions, loss of one
        <italic>PTEN</italic> allele or reduction in its expression may be playing a key role in
        tumor initiation, while further reduction of its function/expression may favor invasion and
        possibly tumor metastasis in advanced cancers.</p>
      <p>In agreement with this hypothesis, it has been reported that primary tumors often show loss
        or alteration of at least one <italic>PTEN</italic> allele (e.g.,
        70%–80% of primary CaPs; <xref ref-type="bibr" rid="pbio.0000059-Gray1">Gray et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000059-Whang1">Whang et al. 1998</xref>), while homozygous inactivation of
          <italic>PTEN</italic> is generally associated with advanced cancer and metastasis (<xref ref-type="bibr" rid="pbio.0000059-Cantley1">Cantley and Neel 1999</xref>; <xref ref-type="bibr" rid="pbio.0000059-Di1">Di Cristofano and Pandolfi 2000</xref>), supporting
        a possible key role for progressive <italic>PTEN</italic> functional loss in tumor
        progression.</p>
      <p>The elucidation of the molecular basis for tumor initiation and progression in most
        epithelial neoplasms has been hindered by the lack of suitable laboratory and preclinical
        models that accurately reflect the genetic and histopathological progression of these
        cancers. Furthermore, the outcome of a progressive dose reduction in tumor suppressor
        function has been rarely assessed in vivo in the mouse. Small interfering RNA (siRNA)
        technology has more recently allowed testing the consequence of knockdown of a tumor
        suppressor such as p53 in specific cell types such as hemopoietic stem cells, by generating
        epi-allelic series of hypomorphs created by stable RNA interference (RNAi) transduction
          (<xref ref-type="bibr" rid="pbio.0000059-Hemann1">Hemann et al. 2003</xref>). In the case
        of Pten, this analysis is further complicated since complete inactivation of the gene
        results in early embryonic lethality and aberrant developmental programs (<xref ref-type="bibr" rid="pbio.0000059-Di2">Di Cristofano et al. 1998</xref>, <xref ref-type="bibr" rid="pbio.0000059-Di4">2001a</xref>; <xref ref-type="bibr" rid="pbio.0000059-Suzuki1">Suzuki et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000059-Podsypanina1">Podsypanina et al. 1999</xref>). Thus, a further
        unrestricted reduction of the Pten dose could still result in embryonic lethality. On the
        other hand, the consequence of complete <italic>Pten</italic> inactivation, even when
        restricted to a specific organ/tissue, could still affect the developmental program of that
        organ, while complete somatic loss of <italic>Pten</italic> in an adult organ would better
        approximate what is normally observed in human cancer. We have addressed these issues for
          <italic>Pten</italic>, as we describe in this article, through the generation of (i)
        hypomorphic mouse mutants and (ii) conditional mutants for complete prostate-specific
          <italic>Pten</italic> inactivation after puberty.</p>
      <p>We previously reported that <italic>Pten</italic> heterozygous
          (<italic>Pten</italic><sup>+/−</sup>) mutants are prone to develop
        neoplasms of various histological origins, including prostatic intraepithelial neoplasias
        (PIN) after a long latency ( &gt;14 mo) and at incomplete penetrance (40%)
          (<xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al. 2001a</xref>).
          <italic>Pten</italic><sup>+/−</sup> mutants, however, never develop
        invasive CaPs. Invasive CaPs were, by contrast, observed in compound
          <italic>Pten</italic><sup>+/−</sup>/<italic>p27<sup>Kip1</sup></italic><sup>+/−</sup>
        or
          <italic>Pten</italic><sup>+/−</sup>/<italic>p27<sup>Kip1</sup></italic><sup>−/−</sup>
          mutants<bold> (</bold><xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al.
          2001a</xref>). These lesions appeared to originate in PIN lesions, which then become
        invasive. However, no metastatic CaP was observed in this model, also in view of early
        lethality due to the occurrence of concomitant tumors of various histogenesis. Analysis of
        tumors, PIN, and CaP in <italic>Pten</italic><sup>+/−</sup> mice and
          <italic>Pten</italic>/<italic>p27<sup>Kip1</sup></italic> compound mutants strongly
        suggested that <italic>Pten</italic> may be haploinsufficient in prostate tumor suppression
        since Pten protein expression was never lost in these lesions. If this was indeed the case,
        a further reduction in the Pten dose with respect to
          <italic>Pten</italic><sup>+/−</sup> mutants should impact on
        tumorigenesis and tumor progression. By contrast, in case Pten needed to be completely lost
        for phenotypic consequences to be manifest, only a complete <italic>Pten</italic>
        inactivation would hasten the neoplastic process.</p>
      <p>The discovery that phosphatidylinositol 3,4,5-trisphosphate (PIP3) is the main in vivo
        substrate of PTEN (<xref ref-type="bibr" rid="pbio.0000059-Maehama1">Maehama and Dixon
        1998</xref>) placed this phosphatase into a well-defined pathway (reviewed in <xref ref-type="bibr" rid="pbio.0000059-Vivanco1">Vivanco and Sawyers 2002</xref>). PIP3 levels
        are very low in quiescent cells, but rapidly increase upon stimulation by growth factors,
        through phosphoinositide 3-kinase (PI3K) activation. The role of PTEN is to keep the levels
        of PIP3 low by dephosphorylation at the D3 position. Loss of PTEN function results in
        increased PIP3 levels and subsequent Akt hyperactivation/phosphorylation (<xref ref-type="bibr" rid="pbio.0000059-Stambolic1">Stambolic et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000059-Di3">Di Cristofano et al. 1999</xref>; <xref ref-type="bibr" rid="pbio.0000059-Backman1">Backman et al. 2002</xref>; <xref ref-type="bibr" rid="pbio.0000059-Vivanco1">Vivanco and Sawyers 2002</xref>). It may
        therefore be proposed that a progressive reduction in the Pten dose could simply result in a
        concomitant progressive dose-dependent increase in Akt activation and its downstream
        molecular biological consequences. Alternatively, <italic>Pten</italic> expression levels
        may constitute discrete biochemical thresholds below which qualitative functional changes
        would occur, contributing to tumor progression and invasion.</p>
      <p>CaP is the most common non-skin malignancy among Western adult males. It is estimated that
        in 2003, approximately 220,900 new cases and 28,900 CaP-related deaths will occur in the
        United States. Approximately 70% of CaP patients will harbor mutation or display
        loss of at least one allele of <italic>PTEN</italic> ensuing in the constitutive activation
        of the PI3K/mTOR pathway (<xref ref-type="bibr" rid="pbio.0000059-Gray1">Gray et al.
        1998</xref>; <xref ref-type="bibr" rid="pbio.0000059-Whang1">Whang et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000059-Di1">Di Cristofano and Pandolfi 2000</xref>). As
        aforementioned, those mutations are in positive correlation with tumor stage and grade,
          <italic>PTEN</italic> being completely lost in approximately 40% of metastatic
        CaPs (<xref ref-type="bibr" rid="pbio.0000059-Gray1">Gray et al. 1998</xref>; <xref ref-type="bibr" rid="pbio.0000059-Whang1">Whang et al. 1998</xref>). We therefore decided
        to focus on the prostate as an important model system to determine genetically whether and
        how the dose of Pten dictates tumor initiation and progression.</p>
      <p>We demonstrate in vivo, in a hypomorphic mouse mutant series, that Pten plays a crucial
        dose-dependent role in CaP tumor suppression and that <italic>Pten</italic> progressive
        inactivation leads to both quantitative and qualitative molecular and biological changes
        towards full-blown tumorigenesis.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Generation of a Hypomorphic <italic>Pten</italic> Mutant Series</title>
        <p>We have previously reported that <italic>Pten</italic> heterozygous mutants are tumor
          prone and viable, while complete <italic>Pten</italic> inactivation results in embryonic
          lethality (<xref ref-type="bibr" rid="pbio.0000059-Di2">Di Cristofano et al. 1998</xref>,
            <xref ref-type="bibr" rid="pbio.0000059-Di4">2001a</xref>). We therefore decided to
          generate and characterize a mouse mutant in which the dose of Pten would be reduced
          further below the levels observed in a
          <italic>Pten</italic><sup>+/−</sup> mutant. To this end, we at first
          engineered by homologous recombination an allele of <italic>Pten</italic> that would
          express a wild-type <italic>Pten</italic> gene at reduced levels, taking advantage of the
          well-known phenomenon of transcriptional interference (<xref ref-type="bibr" rid="pbio.0000059-McDevitt1">McDevitt et al. 1997</xref>; <xref ref-type="bibr" rid="pbio.0000059-Morita1">Morita et al. 2003</xref>). We therefore targeted within
            <italic>Pten</italic> intron 3 the neomycin (Neo) cassette under the control of the
          strong CMV promoter (<xref ref-type="fig" rid="pbio.0000059-g001">Figure 1</xref>A; see
          also <xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>A) in mouse embryonic
          stem (ES) cells. Transcription of the Neo cassette in the recombined allele was expected
          to interfere with the transcription of the <italic>Pten</italic> gene, in turn resulting
          in lower expression levels of a wild-type Pten protein by this allele. Correctly
          recombined ES clones were obtained (see <xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>B; <xref ref-type="sec" rid="s4">see Materials and Methods</xref>) and
          injected into blastocysts for germline transmission. Mutants harboring the
            <italic>Pten</italic><sup>hy</sup> allele were obtained from recombined ES cells and
          were found viable, thriving, and fertile. We next intercrossed
            <italic>Pten</italic><sup>hy/+</sup> mice with
            <italic>Pten</italic><sup>+/−</sup> mice to generate a hypomorphic
          series (<xref ref-type="fig" rid="pbio.0000059-g001">Figure 1</xref>B).</p>
        <fig id="pbio.0000059-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0000059.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Production and Analysis of a <italic>Pten</italic> Hypomorphic Mouse Series</title>
            <p>(A)<bold/> Schematic representation of the wild-type (<italic>+</italic>),
              hypomorphic (<italic>hy</italic>), and null (−) alleles of
              <italic>Pten</italic>. (For a detailed view, see <xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>A.)</p>
            <p>(B) Breeding scheme used to produce a <italic>Pten</italic> hypomorphic mouse series
              and predicted hierarchy of <italic>Pten</italic> expression levels.</p>
            <p>(C) WB analysis of MEF lysates from ten littermate primary cell cultures obtained
              from a single cross (indicated in [B]) confirms predicted
                <italic>Pten</italic> expression hierarchy in the hypomorphic series and inversely
              related Akt phosphorylation status (top), both verified by densitometric analysis and
              plotting of the Pten/actin and phospho-Akt/Akt ratios (bottom).</p>
            <p>(D) MEF cDNA was amplified by semiquantitative PCR with exon 3 (forward) and exon
              4–5 spanning (reverse) primers for <italic>Pten</italic>. Consistent with
              the concept of transcriptional interference at the <italic>Pten</italic> locus,
                <italic>Pten</italic> mRNA levels in <italic>Pten</italic><sup>hy/−</sup>
              MEFs are clearly below the level observed in heterozygosity. Lower panels show the
              quantification of <italic>Pten</italic> relative to <italic>Hprt</italic>
              amplification.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0000059.g001" xlink:type="simple"/>
        </fig>
        <fig id="pbio.0000059-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0000059.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Conditional Knockout of the <italic>Pten</italic> Gene in Mouse Prostate</title>
            <p>(A) Map of wild-type <italic>Pten</italic> locus (top), targeting construct (second
              from top), predicted targeted locus (third from top), <italic>Pten</italic> locus
              after Cre-mediated excision of the Neo resistance cassette by crossing with an
                <italic>EIIA-Cre</italic> mouse (fourth from top), and <italic>Pten</italic> locus
              after Cre-mediated excision of the floxed exons 4 and 5 by crossing with a
                <italic>PB-Cre</italic> or <italic>PB-Cre4</italic> transgenic mouse (bottom). The
              genomic sequence is depicted as a black line, with black boxes representing exons 4
              and 5. Pink and yellow boxes represent the Neo resistance and the HSV thymidine kinase
              cassette (TK) and light blue triangles represent the <italic>loxP</italic> site,
              respectively. The <italic>Pten</italic> genomic fragments used as a probe for Southern
              blot analysis are shown (3′ probe and probe 6.1). Solid arrows represent
              expected fragments following hybridization with the 3′ probe upon digestion
              with <italic>Eco</italic>RI, and dashed arrows represent expected fragments following
              hybridization with the probe 6.1 upon digestion with <italic>Xba</italic>I. Locations
              of PCR primers to detect wild-type, floxed allele
              (<italic>Pten</italic><sup>loxP</sup>), and deleted allele are shown.
              <italic>Xba</italic>I (X), <italic>Kpn</italic>I (K), <italic>Bam</italic>HI (B), and
                <italic>Eco</italic>RI (E) sites are shown.</p>
            <p>(B) Genotyping of mice. Lanes 1 and 2 show Southern blot analysis of ES cell clones
              with 3′ probe of control (lanes 2) and recombined clones and #176 (lane 1)
              after digestion with <italic>Eco</italic>RI, showing a 6 kb wild-type band (WT) and a
              2.5 kb targeted band (R). Lanes 3 and 4 (control) represent Southern blot analysis of
              mouse tail DNA of offspring by crossing F1 mouse generated from #176 with an
                <italic>EIIA-Cre</italic> mouse with probe 6.1 after digestion with
              <italic>Xba</italic>I, showing wild-type, targeted
              (<italic>Pten</italic><sup>loxP-neo</sup>), and floxed
              (<italic>Pten</italic><sup>loxP</sup>) locus bands. Lanes 5, 6 (control), and 7
              represent Southern blot analysis of mouse tail DNA of offspring by crossing the mouse
              of lane 3 with a wild-type mouse with probe 6.1 after digestion with
              <italic>Xba</italic>I. Lanes 8–14 show PCR analysis of tail DNA of offspring
              by crossing a <italic>PB-Cre4</italic> (+),
                <italic>Pten</italic><sup>loxP/+</sup> male with a
                <italic>Pten</italic><sup>loxP/+</sup> female with primers 1 and 2. Lanes
              8, 9, and 14 indicate <italic>Pten</italic><sup>loxP/+</sup> , lanes 10 and
              13 indicate <italic>Pten</italic><sup>+/+</sup>,<sup/>and lanes 11
              and 12 indicate <italic>Pten</italic><sup>loxP/loxP</sup>. Lanes 15–17 show
              PCR analysis of tail DNA of offspring by crossing a
                <italic>Pten</italic><sup>loxp/+</sup> male with a
              <italic>PB-Cre4</italic>(+), <italic>Pten</italic><sup>loxP/+</sup>
              female with primers 1, 2, and 3. Lane 15 indicates
                <italic>Pten</italic><sup>loxP/+</sup>, lane 16 indicates
                <italic>Pten</italic><sup>+/+</sup>, and lane 17 indicates that
              the deleted allele exists in tail DNA of this offspring.</p>
            <p>(C) Representation of crossing scheme used to generate prostate-specific
              <italic>Pten</italic> conditional mutants. <italic>Pten</italic><sup>loxP/loxP</sup>
              mutants were crossed with <italic>PB-Cre</italic> transgenic mice or
              <italic>PB-Cre4</italic> transgenic mice.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0000059.g003" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2b">
        <title>Partial Rescue of Embryonic Lethality in <italic>Pten</italic> Hypomorphic Mutants</title>
        <p>The further reduction of the Pten dose could indeed result in embryonic lethality; we
          therefore assessed whether compound <italic>Pten</italic><sup>hy/−</sup> mice
          would be born at all. In the analyzed cohort (<italic>n</italic> = 190), viable
          male and female <italic>Pten</italic><sup>hy/−</sup> mutants were in fact
          obtained. However, the frequencies among various genotypes did not follow Mendelian
          ratios. Out of the 25% <italic>Pten</italic><sup>hy/−</sup> mutants
          expected in these crosses, only 10% were born. In particular, approximately
          40% of the <italic>Pten</italic><sup>hy/−</sup> males and
          75% of the <italic>Pten</italic><sup>hy/−</sup> females were lost
          during gestation. This strongly suggested that a further reduction of the Pten dose had
          occurred in <italic>Pten</italic><sup>hy/−</sup> mutants and that this reduction
          still results in embryonic lethality, albeit at incomplete penetrance (the embryonic
          phenotype of the <italic>Pten</italic><sup>hy/−</sup> will be described
          elsewhere; L. C. Trotman and P. P. Pandolfi, unpublished data). Enough viable
            <italic>Pten</italic><sup>hy/−</sup> males were obtained, however, and
          monitored for tumorigenesis in the prostate. As predicted, a significant reduction in Pten
          levels and the consequent increase in Akt activation (phospho-Akt/Akt ratio) were observed
          in organs and primary cells from <italic>Pten</italic><sup>hy/−</sup> mutants
          when compared to <italic>Pten</italic><sup>+/−</sup>,
            <italic>Pten</italic><sup>hy/+</sup>, and wild-type littermates. In particular,
          we analyzed mouse embryonic fibroblasts (MEFs), peripheral blood mononuclear cells
          (PBMCs), and prostates of various genotypes (<xref ref-type="fig" rid="pbio.0000059-g001">Figure 1</xref>C; <xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>A and
            <xref ref-type="fig" rid="pbio.0000059-g002">2</xref>B; data not shown).
          Semiquantitative RT–PCR analysis confirmed the reduction of
          <italic>Pten</italic> mRNA expression in <italic>Pten</italic><sup>hy/−</sup>
          MEFs when compared to <italic>Pten</italic><sup>+/−</sup> and wild-type
          cells (see <xref ref-type="fig" rid="pbio.0000059-g001">Figure 1</xref>D).</p>
        <fig id="pbio.0000059-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0000059.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title><italic>Pten</italic><sup>hy/−</sup> Mice Display Massive Hyperplasia
              and Invasive CaP</title>
            <p>(A)<bold/> IHC on preneoplastic anterior prostate (AP) tissue of 2-mo-old littermate
              mice shows decreasing Pten protein levels in the hypomorphic series.</p>
            <p>(B) WB analysis of the prostate lobes from (A) is shown on the left and their
              quantification is shown on the right.</p>
            <p>(C) MRI of <italic>Pten</italic><sup>hy/−</sup> mice aged 6–8 mo
              shows pathologic structures (encircled by dashed lines) adjacent to seminal vesicles
              (SV) coinciding with displacement of the bladder (Bl), features typically associated
              with massive prostate tumors (right). These features were never found in
                <italic>Pten</italic><sup>+/+</sup> or
                <italic>Pten</italic><sup>+/−</sup> mice (left).</p>
            <p>(D) Macroscopic view of the <italic>Pten</italic><sup>hy/−</sup> mouse from
              (C) confirms massive enlargement of the AP lobes, but normal-sized seminal vesicles.</p>
            <p>(E) Quantification of WB analysis on AP lobe total lysates from the
                <italic>Pten</italic><sup>hy/−</sup> animal shown in (C) compared to
              preneoplastic AP of same genotype from (A) and (B), labeled 8 mo and 2 mo,
              respectively. Note that in the enlarged hyperplastic prostate, Pten protein expression
              is retained (levels are expressed relative to the corresponding wild-type animals).</p>
            <p>(F) Histopathology (H&amp;E) of AP lesions at 8 mo reveals transition from low-
              to high-grade PIN and invasion (infiltration of stromal tissue is indicated by arrows)
              in <italic>Pten</italic><sup>hy/−</sup>, while age-matched
                <italic>Pten</italic><sup>+/−</sup> tissue only shows
              hyperplastic features and <italic>Pten</italic><sup>+/+</sup> tissue
              is unaffected. Bars are 50 μm.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0000059.g002" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2c">
        <title>Massive Prostate Hyperplasia and Invasive CaP in
            <italic>Pten</italic><sup>hy/−</sup> Mutants</title>
        <p>The levels of Pten were indeed further reduced in the prostates from
            <italic>Pten</italic><sup>hy/−</sup> mutants when compared to wild-type,
            <italic>Pten</italic><sup>hy/+</sup>, and
            <italic>Pten</italic><sup>+/−</sup> mice (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>A and <xref ref-type="fig" rid="pbio.0000059-g002">2</xref>B). Conversely, Akt activation was increased in
            <italic>Pten</italic><sup>hy/−</sup> mutants (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>B). On this premise, we therefore studied
          prostate tumorigenesis in <italic>Pten</italic><sup>hy/+</sup>
          (<italic>n</italic> = 26),
          <italic>Pten</italic><sup>+/−</sup> (<italic>n</italic> = 24
          in this study plus <italic>n</italic> = 18, as previously reported; <xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al. 2001a</xref>), and
            <italic>Pten</italic><sup>hy/−</sup> (<italic>n</italic> = 14)
          mutants on a comparative basis. Mice were followed throughout their lives according to the
          following experimental scheme: (i) all cohorts were subjected to serial monthly (in
          selected cases, biweekly) nuclear magnetic resonance imaging (MRI) (<xref ref-type="sec" rid="s4">see Materials and Methods</xref>) for detection of morphological changes in the
          size and shape of the prostate; (ii) mice were sacrificed at or prior to tumor detection
          for postmortem pathological analysis or when manifest sign of distress were observed
          (owing to tumor codevelopment; <italic>Pten</italic><sup>hy/−</sup> mutants, as
            <italic>Pten</italic><sup>+/−</sup> mice, in fact, developed tumors
          of multiple histologic origins; data not shown). Striking differences were observed in the
          prostates of these three cohorts over time. The prostates of
            <italic>Pten</italic><sup>+/+</sup> and
            <italic>Pten</italic><sup>+/−</sup> mice were never found enlarged by
          MRI analysis at any age (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>C;
          see <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D).
            <italic>Pten</italic><sup>+/−</sup> mutants developed
          moderate/low-grade PINs at incomplete penetrance (35%–40%
          approximately, after a long latency of &gt;12 mo) that were only detected by serial
          postmortem analysis, as previously reported (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>F; <xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al.
            2001a</xref>). Strikingly, however, MRI analysis immediately revealed a profound
          difference in the <italic>Pten</italic><sup>hy/−</sup> cohort. The prostates of
          these mice were found markedly enlarged, and prostate growths were detected starting at 3
          mo (see <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D). By 6–8
          mo, these growths typically surpassed the size of seminal vesicles (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>C and <xref ref-type="fig" rid="pbio.0000059-g002">2</xref>D). Interestingly, prostate enlargements were not
          accompanied by an overall increase in total body weight or size in
            <italic>Pten</italic><sup>hy/−</sup> mutants (data not shown). Postmortem
          pathological analysis of such mutants confirmed the marked epithelial hyperplasia of the
          prostate (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>F). All lobes were
          found to be hypercellular, with prominent macroscopic enlargements of anterior and
          dorsolateral lobes. Microscopically, the regular and round prostatic glands observed in
          wild-type mice were replaced by large, irregular, and complex glands that contained
          multiple intraluminal papillary projections already at age 2–3 mo. Furthermore,
          many cells had sizeable nuclei, clumped chromatin, and prominent nucleoli, forming foci of
          epithelial dysplasia.<bold> </bold>The phenotype observed in the
            <italic>Pten</italic><sup>hy/−</sup> mice was characterized by a wide spectrum
          of levels of cellular differentiation, which was not typically observed in the
            <italic>Pten</italic><sup>+/−</sup> mice. As we previously reported
          in <italic>Pten</italic><sup>+/−</sup> and
            <italic>Pten</italic><sup>+/−</sup>/<italic>p27<sup>Kip1</sup></italic><sup>−/−</sup>
          mutants (<xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al. 2001a</xref>),
          Pten protein expression was also still retained in the hyperplastic prostates from
            <italic>Pten</italic><sup>hy/−</sup> mutants, and Southern blot analysis
          confirmed retention of the hypomorphic <italic>Pten</italic> allele (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>E; data not shown). Importantly, approximately
          25% of the <italic>Pten</italic><sup>hy/−</sup> mice analyzed at more
          than 6 mo of age showed histological signs of local invasion, with tumor cells disrupting
          the basement membrane of the gland and growing into the surrounding stroma (<xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>F; see <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>E). Thus, strikingly, a further reduction in the
          Pten dose as observed in <italic>Pten</italic><sup>hy/−</sup> mutants when
          compared with <italic>Pten</italic><sup>+/−</sup> mutants does lead to
          massive prostate hyperplasia at complete penetrance and accelerates tumor progression from
          high-grade PIN (grade 3–4 tumor as per the CaP grading system for genetically
          engineered mice; <xref ref-type="bibr" rid="pbio.0000059-Park1">Park et al. 2001</xref>)
          to locally invasive CaP in this mouse model.</p>
        <fig id="pbio.0000059-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0000059.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Molecular Effects of Loss of <italic>Pten</italic> and Biological Comparison of
              All Generated Mouse Models</title>
            <p>(A) Ki-67 staining of AP lobe sections illustrates increasing proliferation with
              decreasing Pten levels (numbers are Ki-67-positive cells per 300 cells counted in
              percent; bars are 50 μm).</p>
            <p>(B) The phospho-Akt/Akt ratio is sharply increased in the prostates of 10-wk-old
                <italic>Pten</italic><sup>pc2</sup> animals, as shown by densitometric
              quantification of WB analysis.</p>
            <p>(C) AP staining with anti-phospho-Akt antibodies reveals strong plasma membrane
              localization of phospho-Akt and apparent reduction of p27 protein detection, whereas
              phospho-mTOR and phospho-threonine-FOXO3 antibodies show increased staining in
                <italic>Pten</italic><sup>pc2</sup> versus wild-type mouse prostates. Bars are 50
              μm.</p>
            <p>(D) Kaplan–Meier curve showing prostate enlargement as visualized by MRI.
              Progressive rates of mass increase for <italic>Pten</italic><sup>pc2</sup> (median
              age, 4 mo), <italic>Pten</italic><sup>hy/−</sup> (median age, 7 mo), and
                <italic>Pten</italic><sup>pc1</sup> (median age, 16 mo) mice are found. In contrast,
              no prostatic size irregularities were detected in
                  <italic>Pten<sup>+/+</sup></italic> or
                  <italic>Pten<sup>+/−</sup></italic> mice.</p>
            <p>(E) Incidence of invasive CaP. Invasive CaP was defined as tumor cells disrupting the
              basal membrane of prostatic glands and growing into the surrounding stroma. Full
              penetrance was observed in both <italic>Pten<sup>pc1</sup></italic> mice as well as in
                  <italic>Pten<sup>pc2</sup></italic> mice. In contrast,
                  <italic>Pten<sup>hy/−</sup></italic> mice with a follow-up of more than
              6 mo displayed only 25% incidence of invasive CaP.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0000059.g005" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2d">
        <title>Generation of Conditional Prostate-Specific <italic>Pten</italic> Mutants</title>
        <p>We next determined whether complete <italic>Pten</italic> inactivation in the prostate
          would further affect CaP tumor progression. To this end, we generated mouse mutants in
          which <italic>Pten</italic> exons 4 and 5 are flanked by <italic>loxP</italic> sites
            (<xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>A; <xref ref-type="sec" rid="s4">see Materials and Methods</xref>). The Neo cassette was excised from the locus
          in vivo by intercrossing <italic>Pten</italic><sup>hy/+</sup> with
            <italic>EIIA-Cre</italic> transgenic mice (<xref ref-type="bibr" rid="pbio.0000059-Lakso1">Lakso et al. 1996</xref>). In these mice, the
          <italic>Cre</italic> recombinase is expressed transiently, early in embryogenesis,
          allowing the production of a mosaic progeny that harbors in the germline
          <italic>Pten</italic> alleles in three different configurations: targeted unmodified
          (still retaining the Neo cassette), <italic>Pten</italic> floxed, or <italic>Pten</italic>
          deleted (<xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>A). Breeding of these
          mosaic mutants allowed us to generate mice heterozygous for the <italic>Pten</italic>
          floxed allele (<italic>Pten</italic><sup>loxP</sup> mutants; see <xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>B).</p>
        <p>As expected, <italic>Pten</italic><sup>loxP</sup> mice were born following Mendelian
          frequencies, viable and fertile, and were utilized for the conditional inactivation of the
            <italic>Pten</italic> gene in the prostate. To this end, we made use of two different
            <italic>Cre</italic> transgenic lines, <italic>PB-Cre</italic> and
          <italic>PB-Cre4</italic>, in which the <italic>Cre</italic> gene is under the control of
          two distinct versions of the rat <italic>Probasin</italic> (<italic>PB</italic>) gene
          promoter (<xref ref-type="bibr" rid="pbio.0000059-Maddison1">Maddison et al. 2000</xref>;
            <xref ref-type="bibr" rid="pbio.0000059-Wu1">Wu et al. 2001</xref>). The
          <italic>PB</italic> gene is expressed in the prostatic epithelium postpuberty since the
          gene is androgen responsive (<xref ref-type="bibr" rid="pbio.0000059-Matusik1">Matusik et
            al. 1986</xref>). Hence, using both <italic>PB-Cre</italic> transgenic lines, excision
          of the <italic>Pten</italic> gene would occur in the prostatic epithelium postpuberty.
          This is of relevance because it avoids any possible developmental effect due to complete
          inactivation of <italic>Pten</italic> during prostate organogenesis. The main difference
          in the two lines essentially resides in the strength of the promoter. In the
            <italic>PB-Cre4</italic> line (<xref ref-type="bibr" rid="pbio.0000059-Wu1">Wu et al.
            2001</xref>), the <italic>Cre</italic> gene is driven by a composite promoter,
              <italic>ARR<sub>2 PB</sub></italic>, which is a derivative of the rat
          <italic>PB</italic> promoter from which the <italic>PB-Cre</italic> line (<xref ref-type="bibr" rid="pbio.0000059-Maddison1">Maddison et al. 2000</xref>) was originally
          generated. <italic>PB-Cre4</italic> mice express <italic>Cre</italic> at high levels and
          at high penetrance, while <italic>PB-Cre</italic> mice express <italic>Cre</italic> at
          lower levels and in fewer cells. This could in turn result in a more focal or more diffuse
          inactivation on <italic>Pten</italic> in the prostatic epithelium, as we could indeed
          document (<xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>A). Also of note,
            <italic>PB-Cre</italic> and <italic>PB-Cre4</italic> mice were crossed with
            <italic>Pten</italic><sup>loxP</sup> mutants in order to generate
            <italic>PB-Cre/Pten</italic><sup>loxP/loxP</sup> (hereafter referred to as
            <italic>Pten</italic><sup>pc1</sup> mutants) or
            <italic>PB-Cre4/Pten</italic><sup>loxP/loxP</sup> (hereafter referred to as
            <italic>Pten</italic><sup>pc2</sup> mutants) (see <xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref>C).</p>
        <fig id="pbio.0000059-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.0000059.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title><italic>Pten</italic><sup>pc2</sup> Mice Develop Invasive CaP</title>
            <p>(A) Histopathology analysis of wild-type, <italic>Pten</italic><sup>pc1</sup>, and
                <italic>Pten</italic><sup>pc2</sup> mice prior to tumor onset. H&amp;E-stained
              AP (top) shows the difference in both the morphology and proliferative rates of the
              prostatic epithelium in these two models. IHC staining with anti-Pten antibody
              (bottom) was carried out on wild-type, <italic>Pten</italic><sup>pc1</sup>, and
                <italic>Pten</italic><sup>pc2</sup> mice. In wild-type mice, strong cytoplasmic
              staining was observed in epithelial cells (arrowheads). In
                <italic>Pten</italic><sup>pc1</sup> mice, staining was generally weak, whereas in
                <italic>Pten</italic><sup>pc2</sup> mice, staining was completely absent in the
              prostatic epithelium. Original magnification, 400×.</p>
            <p>(B) MRI (top) shows massive prostate tumor (surrounded by dashed line) in
                <italic>Pten</italic><sup>pc2</sup> mice (at 6 mo) and no detectable difference
              between the prostates of <italic>Pten</italic><sup>pc1</sup> or
                <italic>Pten</italic><sup>+/+</sup> mice (at 12 mo; arrowheads).
              Bladder (Bl) and seminal vesicles (SV) are indicated. Macroscopic view (second from
              top) of the same animals confirms massive enlargement of both APs in
                <italic>Pten</italic><sup>pc2</sup> and reveals the slightly enlarged AP of
                <italic>Pten</italic><sup>pc1</sup> mice (encircled). H&amp;E staining (bottom)
              of the prostate from <italic>Pten</italic><sup>pc1</sup> mice was characterized by
              multiple foci of PIN lesions and by the presence of prostatic adenocarcinoma. These
              lesions contained well-differentiated neoplastic cells and showed focal areas of
              invasion (arrowheads). H&amp;E stainings of prostates from
                <italic>Pten</italic><sup>pc2</sup> mice showed diffuse, invasive CaP with large,
              undifferentiated tumor cells growing into stromal areas.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0000059.g004" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2e">
        <title>The Dose of Pten Dictates Tumor Progression in the Prostate</title>
        <p>We next studied the impact of complete <italic>Pten</italic> inactivation on prostate
          tumorigenesis in <italic>Pten</italic><sup>pc1</sup> and
          <italic>Pten</italic><sup>pc2</sup> mutants. Mice were followed over time exactly as
          described for the <italic>Pten</italic> hypomorphic series by serial MRI and pathological
          analysis over a period of approximately 18 mo (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D and <xref ref-type="fig" rid="pbio.0000059-g005">5</xref>E). Strikingly, we observed a dramatic difference in
            <italic>Pten</italic><sup>pc1/2</sup> mutants when compared to
            <italic>Pten</italic><sup>hy/−</sup> mutants, but also, importantly, when
          comparing <italic>Pten</italic><sup>pc1</sup> with <italic>Pten</italic><sup>pc2</sup>
          mutants. MRI and macroscopic postmortem analysis of the prostate revealed a rapid massive
          enlargement of all the prostatic lobes already manifested from 2–3 mo of age in
            <italic>Pten</italic><sup>pc2</sup> mutants at complete penetrance (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>B; <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D). In <italic>Pten</italic><sup>pc1</sup>
          mutants, the enlargement was less pronounced at early stages and undetectable by MRI, but
          still apparent (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>B; <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D). As aforementioned, the pattern
          of <italic>Pten</italic> inactivation in the prostatic epithelium was different in
            <italic>Pten</italic><sup>pc1</sup> versus <italic>Pten</italic><sup>pc2</sup> mutants
          (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>A;
            <italic>Pten</italic><sup>pc1</sup> focal versus <italic>Pten</italic><sup>pc2</sup>
          widespread). This difference also correlated with a clear difference in both the
          morphology and proliferative rates of the prostatic epithelium in these two models (see
            <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>A; see also the following
          paragraph). Thus, <italic>Pten</italic><sup>pc2</sup> mutants displayed a much more severe
          prostate enlargement than did <italic>Pten</italic><sup>pc1</sup> mutants (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>B; <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D). <italic>Pten</italic><sup>pc1</sup> mice
          displayed focal areas of epithelial hyperplasia, with enlarged glands formed by relatively
          regular cells, while <italic>Pten</italic><sup>pc2</sup> mice presented disorganized
          hyperplastic glands in all lobes with signs of cellular dysplasia, containing large,
          irregular cells, forming at times cryptic glandular formations (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>A).</p>
        <p>Even more strikingly, however, pathological analysis of prostates from
            <italic>Pten</italic><sup>pc1</sup> and <italic>Pten</italic><sup>pc2</sup> mice
          revealed in both mutants, at complete penetrance, the development of invasive and diffuse
          CaP after a variable latency (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure
          4</xref>B; <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>E). Tumors were in
          both cases made of <italic>Pten</italic> null cells (data not shown). Continuity of local
          invasive disease with that of intraepithelial lumens was often observed. The tumors were
          composed of rather large, mature epithelial cells. Neuroendocrine features, such as
          cytoplasmic granularity and small round cells, were not seen in the tumors analyzed (see
            <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>B). Although the tumors were
          clearly invasive in both <italic>Pten</italic><sup>pc1</sup> and
            <italic>Pten</italic><sup>pc2</sup> mutants with disruption of the basement membrane and
          clear signs of organ infiltration, once again we observed differences in the CaPs from
          these two models. In many instances, in <italic>Pten</italic><sup>pc2</sup> mutants more
          than one prostate lobe was completely effaced by the infiltrating neoplastic cells,
          suggesting a multifocal tumor origin, while invasive tumors in
          <italic>Pten<sup>pc1</sup></italic> mutants were often affecting only one lobe at a time
          and the extent of the infiltration was less diffuse (see <xref ref-type="fig" rid="pbio.0000059-g004">Figure 4</xref>B). In addition, tumors in the
            <italic>Pten</italic><sup>pc1</sup> animals were well-to-moderately differentiated while
          tumors in the <italic>Pten</italic><sup>pc2</sup> mice were in general high-grade,
          undifferentiated lesions. In contrast, <italic>Pten<sup>hy/−</sup></italic>
          mutants displayed a spectrum of phenotypes, from well to undifferentiated and occasionally
          to locally invasive phenotypes, as previously shown.</p>
        <p>Thus, <italic>Pten</italic> conditional inactivation in the prostate leads to invasive
          and diffuse CaP at complete penetrance.</p>
      </sec>
      <sec id="s2f">
        <title>Effects of the Pten Dose on the Biology of the Prostatic Epithelium</title>
        <p>We studied the molecular and biological consequences of Pten dose variations in the
          prostatic epithelium of our various mutants. We included in the analysis age-matched
          (8-wk-old) <italic>Pten</italic><sup>+/+</sup>,
            <italic>Pten</italic><sup>+/−</sup>,
            <italic>Pten</italic><sup>hy/−</sup>, and <italic>Pten</italic><sup>pc2</sup>
          males. The latter mutants were used instead of <italic>Pten</italic><sup>pc1</sup> mice in
          view of the more widespread pattern of <italic>Pten</italic> inactivation observed in
          their prostates.</p>
        <p>First, we determined whether reduction in the Pten dose would affect proliferation of
          epithelial cells. Upon Ki-67 staining, we observed a progressive increase in the
          proliferative rates of prostate epithelial cells, which correlated with the reduction in
            <italic>Pten</italic> expression levels (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>A). For instance, approximately 10-fold more cells were found in active
          proliferation in the prostates from <italic>Pten</italic><sup>pc2</sup> mutants when
          compared with <italic>Pten</italic><sup>+/+</sup> mice. Thus,
            <italic>Pten</italic> inactivation, in a dose-dependent manner, lends to epithelial
          cells a dramatic growth advantage in the prostate. By contrast, MEFs of all genotypes from
          the hypomorphic series did not show noticeable differences in their growth rates under
          standard culture conditions, while showing progressive activation of the Akt signaling
          pathway (data not shown; see <xref ref-type="fig" rid="pbio.0000059-g001">Figure
          1</xref>C). This may reflect an intrinsic differential cell-type sensitivity to
            <italic>Pten</italic> inactivation, also in agreement with the fact that
          <italic>Pten</italic> hypomorphism does not result in overall increased body size and
          weight.</p>
        <p>We next assessed whether and how the progressive reduction of the Pten dose would affect
          the functions of key downstream targets such as Akt, p27<sup>Kip1</sup>, mTOR, and FOXO3
          by immunohistochemistry (IHC) and Western blot (WB) analysis (<xref ref-type="sec" rid="s4">see Materials and Methods</xref>). As aforementioned, we studied the status of
          Akt phosphorylation, the major known biochemical effect of Pten loss (<xref ref-type="bibr" rid="pbio.0000059-Vivanco1">Vivanco and Sawyers 2002</xref>), using an
          anti-phospho-Akt-specific antibody on cells and extracts from the various
          <italic>Pten</italic> mutants. Staining of prostates from various genotypes with this
          antibody increased proportionally to the decrease in Pten levels as confirmed by WB
          analysis (see Figures <xref ref-type="fig" rid="pbio.0000059-g002">2</xref>B, <xref ref-type="fig" rid="pbio.0000059-g005">5</xref>B, and <xref ref-type="fig" rid="pbio.0000059-g005">5</xref>C; data not shown). In addition, IHC analysis revealed a
          drastically different staining pattern in prostate cells from
            <italic>Pten</italic><sup>pc2</sup> mutants when compared with cells from other
          genotypes in that phospho-Akt was found to overtly accumulate at the plasma membrane
            (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>C). A similar staining
          pattern was observed both in <italic>Pten</italic> null epithelium prior to tumor
          occurrence and in cells from overt tumors from both <italic>Pten</italic><sup>pc1</sup>
          and <italic>Pten</italic><sup>pc2</sup> mutants (data not shown). Thus, Akt is
          progressively activated by a reduction in the Pten dose, which in turn results in its
          recruitment to the plasma membrane.</p>
        <p>We next studied the effects of <italic>Pten</italic> inactivation on p27<sup>Kip1</sup>,
          FOXO3, and mTOR, known targets of Akt kinase activity. Phosphorylation of
          p27<sup>Kip1</sup> and FOXO3 by Akt results in their functional inactivation through
          multiple mechanisms such as nuclear export, in the case of FOXO (<xref ref-type="bibr" rid="pbio.0000059-Brunet1">Brunet et al. 1999</xref>), or inhibition of nuclear import
          and downregulation, in the case of p27<sup>Kip1</sup> (<xref ref-type="bibr" rid="pbio.0000059-Mamillapalli1">Mamillapalli et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000059-Liang1">Liang et al. 2002</xref>; <xref ref-type="bibr" rid="pbio.0000059-Shin1">Shin et al. 2002</xref>; <xref ref-type="bibr" rid="pbio.0000059-Viglietto1">Viglietto et al. 2002</xref>). By contrast, Akt activation
          results in mTOR phosphorylation and increased protein translation and translation
          initiation (<xref ref-type="bibr" rid="pbio.0000059-Gingras1">Gingras et al. 2001</xref>).
          We previously reported that the localization or the expression levels of
          p27<sup>Kip1</sup> were not affected in
          <italic>Pten</italic><sup>+/−</sup> and
            <italic>Pten</italic><sup>+/−</sup>/<italic>p27<sup>Kip1</sup></italic><sup>−/−</sup>
          compound mutants (<xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al.
          2001a</xref>). By contrast, a progressive downregulation in p27<sup>Kip1</sup> staining
          was observed in <italic>Pten</italic><sup>hy/−</sup> and
            <italic>Pten</italic><sup>pc2</sup> mutants (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>C; data not shown). p27<sup>Kip1</sup> was
          apparently expressed at lower levels, and fewer cells were found to express the protein
            (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>C). We also studied the
          status of FOXO3 in the various <italic>Pten</italic> mutants, analyzing both its
          localization and threonine phosphorylation with a specific anti-phospho-FOXO3 antibody
            (<xref ref-type="sec" rid="s4">see Materials and Methods</xref>). While no noticeable
          differences were observed in <italic>Pten</italic><sup>+/−</sup> and
            <italic>Pten</italic><sup>hy/−</sup> mutants (data not shown), increase in the
          levels of anti-phospho-FOXO3 cytoplasmic staining were observed in prostate epithelial
          cells from <italic>Pten</italic><sup>pc2</sup> mutants when compared to wild-type mice
            (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>C). Complete
          <italic>Pten</italic> inactivation also resulted in an increase in mTOR phosphorylation in
          the prostatic epithelium of <italic>Pten</italic><sup>pc2</sup> mutants (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>C).</p>
        <p>Thus, the progressive reduction of the Pten dose (and the extent of <italic>Pten</italic>
          inactivation in <italic>Pten</italic><sup>pc1/2</sup> mutants) affects the proliferative
          rate of the prostatic epithelium and results in molecular changes, which in turn dictates
          the natural history of these lesions and tumor progression (<xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>D and <xref ref-type="fig" rid="pbio.0000059-g005">5</xref>E).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>Our analysis allows a detailed deconstruction the molecular genetics underlying cancer
        progression in the prostate and the assessment of the key relevance of Pten and subtle
        variations in its dose in controlling this process. Based on our findings, we can now
        attribute distinct preneoplastic or malignant pathological entities to distinct molecular
        states. Furthermore, this new knowledge allows the reclassification, on the basis of their
        true molecular nature, of pathological lesions that at a superficial analysis appeared very
        similar (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>).</p>
      <fig id="pbio.0000059-g006" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pbio.0000059.g006</object-id>
        <label>Figure 6</label>
        <caption>
          <title>Pten Dose Affects Prostate Tumor Progression</title>
          <p><italic>Pten</italic><sup>+/−</sup> mice develop hyperplasia,
            dysplasia, and low-grade PIN. <italic>Pten</italic><sup>hy/−</sup> mice
            develop at complete penetrance high-grade PIN at a young age (8–10 wk) and
            roughly 25% present invasive CaP around 8 mo.
            <italic>Pten</italic><sup>pc</sup> mice develop invasive CaP at complete penetrance.
            (See Discussion for a detailed description.)
              <italic>p27<sup>Kip1−/−</sup></italic> mice, on the contrary,
            develop only BPH. Possibilities for human therapeutic intervention derived from our
            findings: in addition to inactivation of PI3K/AKT and mTOR enzymatic activities (in
              <italic>PTEN</italic> loss of heterozygosity condition), monitoring and elevation of
            PTEN expression levels of the remaining allele could not only prevent formation of PIN
            lesions (in <italic>PTEN</italic><sup>+/−</sup> individuals), but
            could importantly also be used to counteract the progression to invasive phenotypes (as
            observed in <italic>Pten</italic><sup>hy/−</sup><italic><sup/>
            </italic>mouse mutants).</p>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.0000059.g006" xlink:type="simple"/>
      </fig>
      <p>In this supposedly linear and multistep process, which separates two extremely different
        anatomical and pathological entities, a normal prostatic epithelium from an invasive CaP,
        there are, in between, a discrete number of anatomically distinct intermediary steps, such
        as prostate hyperplasia &gt; displasia/low-grade PIN &gt; high-grade PIN &gt;
        locally invasive CaP &gt; diffused CaP. These entities have been recognized before on
        the basis of their pathological features. The fact that we are now able to correlate these
        anatomical stages with specific molecular events, such as the level of expression of a
        single tumor suppressor gene, not only represents an integration of anatomical, descriptive
        findings with biological data, but also offers the opportunity of therapeutic interventions.</p>
      <p>We show in this study that inactivation of one <italic>Pten</italic> allele in the mouse
        may lead to prostate epithelial hyperplasia, as complete inactivation of p27<sup>Kip1</sup>
        in the mouse leads to what resembles human benign prostate hyperplasia (BPH). However, these
        two lesions are very different in nature and outcome: the first, in fact, impacts only on
        epithelial elements and over time evolves to low-grade PIN, while the second impacts on both
        epithelial and stroma elements, representing hyperplasia of the whole organ, but does not
        evolve toward malignancy (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>;
          <xref ref-type="bibr" rid="pbio.0000059-Cordon-Cardo1">Cordon-Cardo et al. 1998</xref>;
          <xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al. 2001a</xref>). This
        obviously does not exclude that loss of p27<sup>Kip1</sup> expression when accompanied by
        additional genetic events (e.g., loss of PTEN) may lead to a completely different outcome,
        as is also supported by our previous in vivo analysis in the mouse (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>; <xref ref-type="bibr" rid="pbio.0000059-Di4">Di
          Cristofano et al. 2001a</xref>).</p>
      <p>Moreover, our data demonstrate that a further reduction in the Pten dose, as observed in
        the <italic>Pten</italic><sup>hy/−</sup> mutants, accelerates tumor progression
        dramatically, eventually resulting in high-grade PIN and locally invasive carcinoma (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>). This fact has very important
        therapeutic implications. As a large number of CaP patients (more than 80%)
        display at presentation loss of one <italic>PTEN</italic> allele, but do retain the other
        normal <italic>PTEN</italic> allele, it could be proposed that high-grade PIN or locally
        invasive prostate carcinomas could be prevented or treated by pharmacologically modulating
        the expression of the remaining <italic>PTEN</italic> allele or by antagonizing the
        downstream consequences of <italic>PTEN</italic> downregulation or partial inactivation
        (e.g., PI3K/mTOR activation; <xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>).</p>
      <p>While the massive prostate hyperplasia/dysplasia observed in the
          <italic>Pten</italic><sup>hy/−</sup> mutants is not, as expected, accompanied by
        complete loss of <italic>Pten</italic> expression (see <xref ref-type="fig" rid="pbio.0000059-g002">Figure 2</xref>E), the low penetrance of the invasive CaP in these
        mutants strongly suggest that additional events have to occur for this pathological
        transition to occur. Nevertheless, it is important to underscore that
          <italic>Pten</italic><sup>+/−</sup> mice, unlike
          <italic>Pten</italic><sup>hy/−</sup> mutants, do not develop invasive CaP, but
        only low-grade PIN lesions (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>).
        Thus, a further reduction of the Pten dose seems to be essential for this process. Several
        possibilities, not mutually exclusive, could be entertained: (i) a more severe reduction in
        the Pten dose could facilitate cooperative tumorigenesis by rendering the cells permissive
        and sensitive to the activation of additional oncogenic pathways; (ii) the massive prostate
        hyperplasia could facilitate the accumulation of additional genetic hits (including complete
          <italic>Pten</italic> loss) by simply expanding the pool of actively dividing cells; (iii)
        a more severe reduction in the Pten dose could protect cells from apoptotic programs that
        are normally triggered by the occurrence of damaging genetics events.</p>
      <p>The fact that <italic>Pten</italic><sup>hy/−</sup> mutants develop massive
        prostate hyperplasia not accompanied by an overall increase in body weight and size
        underscores the fact that different tissues and organs are differentially sensitive to Pten
        dose variations, the prostatic epithelium being one of the most sensitive. In agreement with
        this notion, MEFs from <italic>Pten</italic><sup>hy/−</sup> mutants do not display
        proliferative advantage in standard culture condition over wild-type MEFs. In this respect,
        it is also important to remember that, unlike
          <italic>p27<sup>Kip1</sup></italic><sup>−/−</sup> mice, which display
        hyperplasia of both stromal and parenchymal components in the prostate (as well as an
        increase in body mass; <xref ref-type="bibr" rid="pbio.0000059-Fero1">Fero et al.
        1996</xref>; <xref ref-type="bibr" rid="pbio.0000059-Kiyokawa1">Kiyokawa et al. 1996</xref>;
          <xref ref-type="bibr" rid="pbio.0000059-Nakayama1">Nakayama et al. 1996</xref>), in
          <italic>Pten</italic><sup>hy/−</sup> mutants it is specifically the prostatic
        epithelium that actively proliferates, leading to prostate hyperplasia (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>). Interestingly, this does not parallel what is
        observed in other model systems, such as <italic>Drosophila</italic>, where dose variations
        in the expression of <italic>Pten</italic> or downstream signaling components (e.g., TOR) do
        result in variations in body size and mass (reviewed in <xref ref-type="bibr" rid="pbio.0000059-Oldham1">Oldham and Hafen 2003</xref>).</p>
      <p>While we and others had previously implicated <italic>Pten</italic> heterozygous loss in
        prostate tumorigenesis when in cooperation with additional oncogenic events (such as loss of
          p27<sup>Kip1</sup> or <italic>Nkx3.1</italic> or the expression of the large T oncogene;
          <xref ref-type="bibr" rid="pbio.0000059-Di4">Di Cristofano et al. 2001a</xref>; <xref ref-type="bibr" rid="pbio.0000059-Kwabi-Addo1">Kwabi-Addo et al. 2001</xref>; <xref ref-type="bibr" rid="pbio.0000059-Kim1">Kim et al. 2002</xref>; <xref ref-type="bibr" rid="pbio.0000059-Abate-Shen1">Abate-Shen et al. 2003</xref>), we demonstrate in this
        article that complete inactivation of <italic>Pten</italic> alone in the prostate has
        already catastrophic consequences leading to invasive, diffuse, and highly aggressive
        malignancies (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>). Although it
        cannot be formally excluded that complete <italic>Pten</italic> loss would still cooperate
        with additional oncogenic events toward full-blown transformation, this finding underscores
        once more the exquisite sensitivity of the prostatic epithelium to loss of
        <italic>Pten</italic>. This information should be factored in when tailoring the treatment
        of CaP or high-grade PIN lesions that have completely lost <italic>PTEN</italic> function.
        These lesions may be extremely sensitive to PI3K or mTOR inhibitors, while modulation of
          <italic>PTEN</italic> expression would not be a therapeutic option in these cases (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>). On the basis of these findings,
        it would seem therefore of paramount importance to routinely assess the status of the
          <italic>PTEN</italic> gene and its expression in human CaPs and precancerous lesions as a
        key biomarker to opt for the most appropriate therapeutic or chemopreventive intervention
        modalities. It remains to be seen whether complete <italic>Pten</italic> inactivation in the
        mouse prostate also influences the metastatic potential of these invasive CaPs alone or in
        combination with additional oncogenic events. In this respect, while MRI and postmortem
        analyses have indeed revealed the presence of lung neoplastic lesions in our conditional
          <italic>Pten</italic> mutants, morphological and molecular analyses have so far excluded
        the metastatic nature of these tumors (M. Niki et al., unpublished data).</p>
      <p>The stepwise reduction in the Pten dose results in clear <italic>progressively
        quantitative</italic> changes in the prostate epithelial cells prior to tumor development.
        Increased cellular proliferation correlates with increased phosphorylation of Akt. In
          <italic>Pten</italic> null epithelial cells, both in the preneoplastic stage or in overt
        CaPs, phospho-Akt is found to accumulate almost exclusively at the plasma membrane (see
          <xref ref-type="fig" rid="pbio.0000059-g005">Figure 5</xref>C). Whether this represents
        the extreme consequence of Akt superactivation or rather reflects a genuine qualitative
        change in Akt biology and function in <italic>Pten</italic> null prostate epithelial cells
        remains to be determined. It also remains to be resolved whether the reduction in
          p27<sup>Kip1</sup> expression is also associated with its cytoplasmic relocalization, as
        previously reported in human breast cancer cells suffering AKT hyperactivation (<xref ref-type="bibr" rid="pbio.0000059-Liang1">Liang et al. 2002</xref>; <xref ref-type="bibr" rid="pbio.0000059-Shin1">Shin et al. 2002</xref>; <xref ref-type="bibr" rid="pbio.0000059-Viglietto1">Viglietto et al. 2002</xref>). Taken together, this analysis
        supports a Pten dose-dependent model with <italic>progressive</italic> changes at the
        molecular level, arguing against a Pten threshold model for tumor suppression.</p>
      <p>By contrast, clear <italic>qualitative</italic> morphological changes were observed in the
        prostate epithelium when analyzing the <italic>Pten</italic> hypomorphic series. While
          <italic>Pten</italic><sup>+/−</sup> mice never display massive
        prostatic enlargement, further reduction to <italic>Pten</italic><sup>hy/−</sup>
        levels leads to a sharp increase in prostate mass. In addition,
          <italic>Pten</italic><sup>+/−</sup> mice never develop invasive CaP,
        whereas <italic>Pten</italic><sup>hy/−</sup> mice do (<xref ref-type="fig" rid="pbio.0000059-g006">Figure 6</xref>). These data clearly support a threshold model for
        Pten tumor suppression at the physiopathological level.</p>
      <p>Similarly, qualitative morphological changes are also caused by the number of cells
        suffering complete <italic>Pten</italic> inactivation, as observed when comparing
          <italic>Pten</italic><sup>pc1</sup> versus <italic>Pten</italic><sup>pc2</sup> mice. In
          <italic>Pten</italic><sup>pc2</sup> mice, signs of cellular dysplasia and irregular
        glandular formations were frequently observed, but they were mostly absent from
          <italic>Pten</italic><sup>pc1</sup> mutants. Along the same tenet, profound mass increase
        was always observed at early timepoints in <italic>Pten</italic><sup>pc2</sup> mice, but not
        in <italic>Pten</italic><sup>pc1</sup> mutants. This is likely due to the marked difference
        in the number of <italic>Pten</italic> null cells present in the parenchyma of these two
        models at puberty, reflecting the different levels of <italic>Cre</italic><bold> </bold>expression in the two models. These observations are also consistent with a
        threshold model for <italic>Pten</italic> tumor suppression as a function of the number of
          <italic>Pten</italic> null cells in a given organ.</p>
      <p>From a biological standpoint, it will be challenging to determine in the future whether
        this “field effect” would also play a role in the natural history of
        human CaP. On the one hand, it could be speculated that human CaP likely arises from a
        single transformed cell and that therefore that the field effects observed in mouse models
        will not be critical determinants in the natural history of the human disease. On the other
        hand, the multistep nature of the neoplastic process (and hence the genetic heterogeneity of
        the lesion) and the fact that the tumor will eventually grow to form
        “fields” of neoplastic cells may suggest that these effects, as well as
        stromal and parenchymal interactions, are key aspects of the human disease that the mouse
        model can recapitulate.</p>
      <p>Taken together, our findings demonstrate the key importance of Pten in CaP tumor
        suppression and the dramatic impact that subtle changes in Pten levels and extent of
          <italic>Pten</italic> inactivation may have on tumor initiation and progression in the
        prostate.</p>
    </sec>
    <sec id="s4">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title/>
        <sec id="s4a1">
          <title>Mice</title>
          <p>Generation and characterization of
            <italic>Pten</italic><sup>+/−</sup> mice have been described
            perviously (<xref ref-type="bibr" rid="pbio.0000059-Di2">Di Cristofano et al.
            1998</xref>, <xref ref-type="bibr" rid="pbio.0000059-Di4">2001a</xref>). Mice were
            genotyped by PCR on tail DNA or by Southern blotting as shown. Hypomorphic mice were
            generated as described in <xref ref-type="fig" rid="pbio.0000059-g001">Figure 1</xref>
            and <xref ref-type="fig" rid="pbio.0000059-g003">Figure 3</xref> and tail DNA genotyped
            by PCR for presence of the <italic>Pten</italic><bold><sup>−</sup>
            </bold> and <italic>Pten</italic><sup>hy</sup> alleles (using primers 1 and 2 described
            below) or by Southern blotting.</p>
        </sec>
        <sec id="s4a2">
          <title>Targeting vector and generation of prostate-specific
            <italic>Pten</italic>-deficient mice</title>
          <p>A 129/Sv mouse genomic library (Stratagene, La Jolla, California, United States) was
            screened with a mouse <italic>Pten</italic> probe containing exons 4–6. To
            generate the targeting construct, a 4.1 Kb
            <italic>Kpn</italic>I–<italic>Bam</italic>HI fragment containing 5′
              <italic>Pten</italic> genomic DNA and a 2.0 Kb <italic>Xba</italic>I fragment
            containing 3′ genomic DNA were cloned into pPNT. The targeting construct was
            linearized with <italic>Not</italic>I and electroporated into CJ7 ES cells.
            Transfectants were selected in G418 (350 μg/ml) and gancyclovir (2 μM) and
            expanded for Southern blot analysis using a 3′ probe. Chimeric mice were
            produced by microinjection of two independently generated targeted ES cell clones with
            normal karyotypes into E3.5 C57BL6/J blastocysts, then transferred to pseudopregnant
            foster mothers. Chimeric males were mated with C57BL6/J females (Jackson Laboratory, Bar
            Harbor, Maine, United States), and germline transmission of the mutant allele was
            verified by Southern blot analysis of tail DNA from agouti coat-colored F1 offspring.
            Next, <italic>Pten</italic><sup>loxP-neo/+</sup> mice were mated with
              <italic>EIIA-Cre</italic> transgenic mice (<xref ref-type="bibr" rid="pbio.0000059-Lakso1">Lakso et al. 1996</xref>), and tail DNA from offspring was
            subjected to Southern blot analysis using probe 6.1. Through these crosses, mosaic mice
            harboring a <italic>Pten</italic> wild-type allele, a <italic>Pten</italic> targeted
            allele (<italic>Pten</italic><sup>loxP-neo</sup>), and a floxed allele
              (<italic>Pten</italic><sup>loxp</sup>) in their germline were generated. These mosaic
            mutants were mated with wild-type mice and tail DNA from offspring subjected to Southern
            blot analysis using probe 6.1 and to PCR analysis using primer 1
            (5′-AAAAGTTCCCCTGCTGATGATTTGT-3′) and primer 2
            (5′-TGTTTTTGACCAATTAAAGTAGGCTGTG-3′). PCR conditions were 35 cycles
            (30 sec at 95°C, 1 min at 55°C, and 1 min at 72°C) using
            HotStarTaq Master Mix (Qiagen, Valencia, California, United States), primer (0.25
            μM), and DNA (50 ng). To detect the deleted allele, primer 3
            (5′-CCCCCAAGTCAATTGTTAGGTCTGT-3′) was used.
              <italic>Pten</italic><sup>loxP/loxP</sup> mice were next mated with
            <italic>PB-Cre</italic> transgenic mice (<xref ref-type="bibr" rid="pbio.0000059-Maddison1">Maddison et al. 2000</xref>) or male
            <italic>PB-Cre4</italic> transgenic mice (<xref ref-type="bibr" rid="pbio.0000059-Wu1">Wu et al. 2001</xref>) for conditional prostate-specific <italic>Pten</italic>
            inactivation.</p>
        </sec>
        <sec id="s4a3">
          <title>Autopsy and histopathology</title>
          <p>Animals were autopsied and all tissues were examined regardless of their pathological
            status. Normal and tumor tissue samples were fixed in 10% buffered formalin
            and embedded in paraffin. Sections (5 μm) were stained with hematoxylin and eosin
            (H&amp;E) according to standard protocols.</p>
        </sec>
        <sec id="s4a4">
          <title>Cells</title>
          <p>Primary MEFs derived from ten littermate embryos were produced as follows. MEFs were
            obtained by crossing <italic>Pten</italic><sup>hy/+</sup> and
              <italic>Pten</italic><sup>+/−</sup> animals, embryos were harvested
            at 13.5 dpc, and individual MEFs were produced and cultured as previously described
              (<xref ref-type="bibr" rid="pbio.0000059-Di5">Di Cristofano et al. 2001b</xref>) and
            genotyped as described above. At passage 2, cells were harvested for WB analysis (see
            below) and mRNA extraction by the TRIZOL method (GIBCO–BRL, Carlsbad,
            California, United States) and cDNA produced using the SuperScript First-Strand Kit for
            RT–PCR (Invitrogen, Carlsbad, California, United States) according to the
            manufacturers' instructions. Semiquantitative PCR (yielding a 102 bp amplicon) was
            performed with a <italic>Pten</italic> exon 3-specific forward
            (5′-TGGATTCAAAGCATAAAAACCATTAC-3′) and an exon 4- and exon
            5-specific reverse primer (5′-CAAAAGGATACTGTGCAACTCTGC-3′) using 30
            cycles of 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C) with
            the PCR optimizer kit (Invitrogen) and buffer A according to the manufacturer's
            protocols. PCR amplification of the cDNAs was performed for 25, 30, and 35 cycles, and
            the amplified products were found to be in the linear range at 30 cycles. PCR products
            from hypoxanthine phosphoribosyltransferase (<italic>HPRT</italic>) control
            amplification with 5′-CCTGCTGGATTACATTAAAGCACTG-3′ and
            5′-GTCAAGGGCATATCCAACAACAAAC-3′ primers were used as standards (352
            bp amplicon). For measuring proliferative rates of all MEF genotypes, cells were seeded
            in 12-well plates at 3,000 cells per well in medium containing 10% FBS and
            fixed at 2-d intervals. Analysis and quantification were performed as previously
            described (<xref ref-type="bibr" rid="pbio.0000059-Di5">Di Cristofano et al.
            2001b</xref>).</p>
        </sec>
        <sec id="s4a5">
          <title>WB analysis and densitometry</title>
          <p>Prostates from dissected animals of all genotypes were briefly homogenized (using a
            Polytron homogenizer; Polytron Vertrieb, Bad Wildbad, Germany), and primary MEFs were
            harvested and directly lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA,
            0.1% NP-40, 1 mM sodium ortho-vanadate (Na<sub>3</sub>VO<sub>4</sub>), 10 mM
            NaF, and protease inhibitor cocktail (Hoffmann–La Roche, Basel, Switzerland)
            and cleared by centrifugation; concentrations were determined by the Bio-Rad Protein
            Assay (Bio-Rad Laboratories, Hercules, California, United States); and samples were
            taken into an SDS sample loading buffer.<bold> </bold>Blood was taken from the
            retro-orbital cavity of anesthetized mice, red cells were lysed in lysis buffer (0.155 M
              NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 1 mM EDTA), and intact cells harvested by
            centrifugation. PBMCs were lysed in lysis buffer as previously described (<xref ref-type="bibr" rid="pbio.0000059-Di5">Di Cristofano et al. 2001b</xref>), and protein
            concentrations were determined as above. Equivalents of 50 μg of lysate per lane
            were used for SDS–PAGE and WB analysis. Proteins were detected using a rabbit
            polyclonal anti-Pten antibody (anti-PTEN/MMAC-1 Ab-2; NeoMarkers, Lab Vision
            Corporation, Fremont, California, United States), anti-actin monoclonal antibody (mAb)
            AC-74 (Sigma, St. Louis, Missouri, United States) for normalization, and the Phospho-Akt
            Pathway Sampler Kit antibodies against Akt and phospho-Serine 473 of Akt (Cell Signaling
            Technology, Beverly, Massachusetts, United States) following the manufacturers'
            instructions. After visualization with the ECL system (Amersham Biosciences, Little
            Chalfont, United Kingdom), films were scanned and band density was quantified using
            MacBas v2.5 (Fuji Photo Film Company, Tokyo, Japan) on a Macintosh computer (Apple
            Computer, Sunnyvale, California, United States).</p>
        </sec>
        <sec id="s4a6">
          <title>IHC</title>
          <p>Tissues were fixed in 4% paraformaldehyde and embedded in paraffin, and 8
            μm-thick sections were prepared. Anti-p27 mouse mAb (catalog #610242; BD
            Transduction Laboratories, San Diego, California, United States) was used at 0.5
            μg/ml concentration. The IHC detection was performed with the MOM kit from Vector
            Laboratories (Burlingame, California, United States). Rabbit polyclonal phospho-Akt (Ser
            473) antibody (catalog #9270 from Cell Signaling Technology) was used in 1:50 dilution,
            and rabbit polyclonal antibody PTEN/MMAC1 Ab-2 (catalog #RB-072-PO from NeoMarkers) was
            used at 1:200 dilution. The IHC detection was performed with the ABC kit from Vector
            Laboratories. These staining procedures were carried out by the automated staining
            processor Discovery from Ventana Medical Systems (Tucson, Arizona, United States).</p>
          <p>Anti-Ki-67 antibody (Novocastra Laboratories Ltd., Newcastle-upon-Tyne, United
            Kingdom), anti-Cre antibody (Novagen, Madison, Wisconsin, United States), and polyclonal
            anti-phospho-mTOR antibody (Cell Signaling Technology) were purchased.
            Anti-phospho-FOXO3 (Thr 32) was a kind gift from Anne Brunet (Harvard University,
            Cambridge, Massachusetts, United States). Paraffin sections (5 μm thickness) were
            fixed in ice-cold acetone and incubated in 0.1% H<sub>2</sub>O<sub>2</sub>
            for 15 min to inactivate internal peroxidase. Antigen retrieval was performed in 10 mM
            citric acid for 15 min using microwave. IHC staining was performed using biotinylated
            secondary antibodies followed by the Vectastain ABC Elite kit (Vector Laboratories).</p>
        </sec>
        <sec id="s4a7">
          <title>MRI analysis</title>
          <p>Mice were assessed individually by MRI for tumor establishment. Images were obtained on
            a 1.5T General Electric LX Echo Speed Signa scanner (General Electric Medical Systems,
            Milwaukee, Wisconsin, United States) using homemade foil solenoid coils (22 mm or 27 mm
            inner diameter). The mice were anesthetized with isofluorane. Images were acquired using
            a two-dimensional spin-echo pulse sequence. Initially, the animal was positioned in the
            coil in a holder, and sagittal scout (field of view, 120 mm) images obtained (TR
            = 300 ms, TE = 14 ms, one excitation per phase-encoding step, 256
            × 128 matrix, 3.0 mm-thick slice, 1.5 mm slice separation) to localize the
            region of interest. Subsequently, high-quality T<sub>2</sub>-weighted fast spin-echo
            transverse images were obtained (TR = 3,000–5,000 ms,
            TE<sub>eff</sub> = 102 ms, echo train length = 12, 6–12
            excitations per phase-encoding step, 1.5 mm thick slice, field of view = 40
            mm, 0.5 mm slice separation, in plane resolution of 156 ×156 μm or 156
            × 208 μm).</p>
        </sec>
        <sec id="s4a8">
          <title>Statistical analysis</title>
          <p>Survival was calculated using the Kaplan–Meier method. Log rank tests were
            used to compare groups by using the SPSS 10 software package (SPSS Incorporated,
            Chicago, Illinois, United States).</p>
        </sec>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Peter Scardino and Howard Scher for advice and discussions; Zhenbang Chen for help
        with genotyping and characterization of the <italic>Pten</italic> hypomorphic mutants;
        Lisette Anne Maddison for the genotyping of the <italic>PR-Cre</italic> transgenic mice;
        Katia Manova and Craig Farrell for assistance with the automated IHC procedures; Maria
        Socorro Jiao for assistance with pathological analysis; and Mihaela Lupu and Cornelia Matei
        for assistance with the MRI analysis. This study was supported, in part, by National Cancer
        Institute (NCI) grants (SPORE 92629 in Prostate Cancer, MMHCC CA-84292, and RO1 CA-82328)
        and by the I.T. Hirschl/M. Weill–Caulier Foundation to PPP and CC-C. Imaging
        analysis was supported by NCI grant R24CA83084 and an MSKCC NCI Core Grant to JAK.</p>
    </ack>
    
    <ref-list>
      <title>References</title>
      <ref id="pbio.0000059-Abate-Shen1">
        <label>1</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Abate-Shen</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Banach-Petrosky</surname>
              <given-names>WA</given-names>
            </name>
            <name name-style="western">
              <surname>Sun</surname>
              <given-names>X</given-names>
            </name>
            <name name-style="western">
              <surname>Economides</surname>
              <given-names>KD</given-names>
            </name>
            <name name-style="western">
              <surname>Desai</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nkx3.1: <italic>Pten</italic> mutant mice develop invasive prostate
            adenocarcinoma and lymph node metastases.</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>3886</fpage>
          <lpage>3890</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Backman1">
        <label>2</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Backman</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Stambolic</surname>
              <given-names>V</given-names>
            </name>
            <name name-style="western">
              <surname>Mak</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>PTEN function in mammalian cell size regulation.</article-title>
          <source>Curr Opin Neurobiol</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>516</fpage>
          <lpage>522</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Brunet1">
        <label>3</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Brunet</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Bonni</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Zigmond</surname>
              <given-names>MJ</given-names>
            </name>
            <name name-style="western">
              <surname>Lin</surname>
              <given-names>MZ</given-names>
            </name>
            <name name-style="western">
              <surname>Juo</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Akt promotes cell survival by phosphorylating and inhibiting a Forkhead
            transcription factor.</article-title>
          <source>Cell</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>857</fpage>
          <lpage>868</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Cantley1">
        <label>4</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Cantley</surname>
              <given-names>LC</given-names>
            </name>
            <name name-style="western">
              <surname>Neel</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>New insights into tumor suppression: PTEN suppresses tumor formation by
            restraining the phosphoinositide 3-kinase/AKT pathway.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>4240</fpage>
          <lpage>4245</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Cordon-Cardo1">
        <label>5</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Cordon-Cardo</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Koff</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Drobnjak</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Capodieci</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Osman</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Distinct altered patterns of p27<italic>
              <sup>KIP1</sup>
            </italic> gene expression in benign prostatic hyperplasia and prostatic carcinoma.</article-title>
          <source>J Natl Cancer Inst</source>
          <year>1998</year>
          <volume>90</volume>
          <fpage>1284</fpage>
          <lpage>1291</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Di1">
        <label>6</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Di Cristofano</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Pandolfi</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title>The multiple roles of <italic>PTEN</italic> in tumor suppression.</article-title>
          <source>Cell</source>
          <year>2000</year>
          <volume>100</volume>
          <fpage>387</fpage>
          <lpage>390</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Di2">
        <label>7</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Di Cristofano</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Pesce</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Cordon-Cardo</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Pandolfi</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title>Pten is essential for embryonic development and tumour suppression.</article-title>
          <source>Nat Genet</source>
          <year>1998</year>
          <volume>19</volume>
          <fpage>348</fpage>
          <lpage>355</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Di3">
        <label>8</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Di Cristofano</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Kotsi</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Peng</surname>
              <given-names>YF</given-names>
            </name>
            <name name-style="western">
              <surname>Cordon-Cardo</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Elkon</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impaired Fas response and autoimmunity in
              <italic>Pten</italic><sup>+/−</sup> mice.</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>285</volume>
          <fpage>2122</fpage>
          <lpage>2125</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Di4">
        <label>9</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Di Cristofano</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>De Acetis</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Koff</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Cordon-Cardo</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Pandolfi</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title><italic>Pten</italic> and p27<italic>
              <sup>KIP1</sup>
            </italic> cooperate in prostate cancer tumor suppression in the mouse.</article-title>
          <source>Nat Genet</source>
          <year>2001a</year>
          <volume>27</volume>
          <fpage>222</fpage>
          <lpage>224</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Di5">
        <label>10</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Di Cristofano</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Niki</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Zhao</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Karnell</surname>
              <given-names>FG</given-names>
            </name>
            <name name-style="western">
              <surname>Clarkson</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>p62<sup>dok</sup>, a negative regulator of ras and mitogen-activated
            protein kinase (MAPK) activity, opposes leukemogenesis by p210<sup>bcr-abl</sup>.</article-title>
          <source>J Exp Med</source>
          <year>2001b</year>
          <volume>194</volume>
          <fpage>275</fpage>
          <lpage>284</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Fero1">
        <label>11</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Fero</surname>
              <given-names>ML</given-names>
            </name>
            <name name-style="western">
              <surname>Rivkin</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Tasch</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Porter</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Carow</surname>
              <given-names>CE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A syndrome of multiorgan hyperplasia with features of gigantism,
            tumorigenesis, and female sterility in p27<sup>Kip1</sup>-deficient mice.</article-title>
          <source>Cell</source>
          <year>1996</year>
          <volume>85</volume>
          <fpage>733</fpage>
          <lpage>744</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Gingras1">
        <label>12</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Gingras</surname>
              <given-names>AC</given-names>
            </name>
            <name name-style="western">
              <surname>Raught</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Sonenberg</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Regulation of translation initiation by FRAP/mTOR.</article-title>
          <source>Genes Dev</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>807</fpage>
          <lpage>826</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Gray1">
        <label>13</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Gray</surname>
              <given-names>IC</given-names>
            </name>
            <name name-style="western">
              <surname>Stewart</surname>
              <given-names>LM</given-names>
            </name>
            <name name-style="western">
              <surname>Phillips</surname>
              <given-names>SM</given-names>
            </name>
            <name name-style="western">
              <surname>Hamilton</surname>
              <given-names>JA</given-names>
            </name>
            <name name-style="western">
              <surname>Gray</surname>
              <given-names>NE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation and expression analysis of the putative prostate tumour-suppressor
            gene <italic>PTEN</italic>.</article-title>
          <source>Br J Cancer</source>
          <year>1998</year>
          <volume>78</volume>
          <fpage>1296</fpage>
          <lpage>1300</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Hemann1">
        <label>14</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hemann</surname>
              <given-names>MT</given-names>
            </name>
            <name name-style="western">
              <surname>Fridman</surname>
              <given-names>JS</given-names>
            </name>
            <name name-style="western">
              <surname>Zilfou</surname>
              <given-names>JT</given-names>
            </name>
            <name name-style="western">
              <surname>Hernando</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Paddison</surname>
              <given-names>PJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An epi-allelic series of p53 hypomorphs created by stable RNAi produces
            distinct tumor phenotypes <italic>in vivo</italic>.</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>33</volume>
          <fpage>396</fpage>
          <lpage>400</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Kim1">
        <label>15</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kim</surname>
              <given-names>MJ</given-names>
            </name>
            <name name-style="western">
              <surname>Cardiff</surname>
              <given-names>RD</given-names>
            </name>
            <name name-style="western">
              <surname>Desai</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Banach-Petrosky</surname>
              <given-names>WA</given-names>
            </name>
            <name name-style="western">
              <surname>Parsons</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of
            prostate carcinogenesis.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>2884</fpage>
          <lpage>2289</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Kiyokawa1">
        <label>16</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kiyokawa</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Kineman</surname>
              <given-names>RD</given-names>
            </name>
            <name name-style="western">
              <surname>Manova-Todorova</surname>
              <given-names>KO</given-names>
            </name>
            <name name-style="western">
              <surname>Soares</surname>
              <given-names>VC</given-names>
            </name>
            <name name-style="western">
              <surname>Hoffman</surname>
              <given-names>ES</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor
            function of p27(Kip1).</article-title>
          <source>Cell</source>
          <year>1996</year>
          <volume>85</volume>
          <fpage>721</fpage>
          <lpage>732</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Knudson1">
        <label>17</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <collab xlink:type="simple">Knudson AG Jr</collab>
          <article-title>Mutation and cancer: Statistical study of retinoblastoma.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1971</year>
          <volume>68</volume>
          <fpage>820</fpage>
          <lpage>823</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Kwabi-Addo1">
        <label>18</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Kwabi-Addo</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Giri</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Schmidt</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Podsypanina</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Parsons</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Haploinsufficiency of the <italic>Pten</italic> tumor suppressor gene
            promotes prostate cancer progression.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>11563</fpage>
          <lpage>11568</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Lakso1">
        <label>19</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lakso</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Pichel</surname>
              <given-names>JG</given-names>
            </name>
            <name name-style="western">
              <surname>Gorman</surname>
              <given-names>JR</given-names>
            </name>
            <name name-style="western">
              <surname>Sauer</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Okamoto</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficient <italic>in vivo</italic> manipulation of mouse genomic sequences
            at the zygote stage.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1996</year>
          <volume>93</volume>
          <fpage>5860</fpage>
          <lpage>5865</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Liang1">
        <label>20</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Liang</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Zubovitz</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Petrocelli</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Kotchetkov</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Connor</surname>
              <given-names>MK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes
            p27-mediated G1 arrest.</article-title>
          <source>Nat Med</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>1153</fpage>
          <lpage>1160</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Maddison1">
        <label>21</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Maddison</surname>
              <given-names>LA</given-names>
            </name>
            <name name-style="western">
              <surname>Nahm</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>DeMayo</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Greenberg</surname>
              <given-names>NM</given-names>
            </name>
          </person-group>
          <article-title>Prostate specific expression of Cre recombinase in transgenic mice.</article-title>
          <source>Genesis</source>
          <year>2000</year>
          <volume>26</volume>
          <fpage>154</fpage>
          <lpage>156</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Maehama1">
        <label>22</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Maehama</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Dixon</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>The tumor suppressor, <italic>PTEN/MMAC1</italic>, dephosphorylates the
            lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.</article-title>
          <source>J Biol Chem</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>13375</fpage>
          <lpage>13378</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Mamillapalli1">
        <label>23</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Mamillapalli</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Gavrilova</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Mihaylova</surname>
              <given-names>VT</given-names>
            </name>
            <name name-style="western">
              <surname>Tsvetkov</surname>
              <given-names>LM</given-names>
            </name>
            <name name-style="western">
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title><italic>PTEN</italic> regulates the ubiquitin-dependent degradation of the
            CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2).</article-title>
          <source>Curr Biol</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>263</fpage>
          <lpage>267</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Matusik1">
        <label>24</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Matusik</surname>
              <given-names>RJ</given-names>
            </name>
            <name name-style="western">
              <surname>Kreis</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>McNicol</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Sweetland</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Mullin</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of prostatic genes: Role of androgens and zinc in gene
            expression.</article-title>
          <source>Biochem Cell Biol</source>
          <year>1986</year>
          <volume>64</volume>
          <fpage>601</fpage>
          <lpage>607</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-McDevitt1">
        <label>25</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>McDevitt</surname>
              <given-names>MA</given-names>
            </name>
            <name name-style="western">
              <surname>Shivdasani</surname>
              <given-names>RA</given-names>
            </name>
            <name name-style="western">
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
            <name name-style="western">
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>A “knockdown” mutation created by
            <italic>cis</italic>-element gene targeting reveals the dependence of erythroid cell
            maturation on the level of transcription factor GATA-1.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1997</year>
          <volume>94</volume>
          <fpage>6781</fpage>
          <lpage>6785</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Morita1">
        <label>26</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Morita</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Ohneda</surname>
              <given-names>O</given-names>
            </name>
            <name name-style="western">
              <surname>Yamashita</surname>
              <given-names>T</given-names>
            </name>
            <name name-style="western">
              <surname>Takahashi</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Suzuki</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HLF/HIF-2α is a key factor in retinopathy of prematurity in
            association with erythropoietin.</article-title>
          <source>EMBO J</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>1134</fpage>
          <lpage>1146</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Nakayama1">
        <label>27</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Nakayama</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Ishida</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Shirane</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Inomata</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Inoue</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mice lacking p27<sup>Kip1</sup> display increased body size, multiple organ
            hyperplasia, retinal dysplasia, and pituitary tumors.</article-title>
          <source>Cell</source>
          <year>1996</year>
          <volume>85</volume>
          <fpage>707</fpage>
          <lpage>720</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Oldham1">
        <label>28</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Oldham</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Hafen</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Insulin/IGF and target of rapamycin signaling: A TOR de force in growth
            control.</article-title>
          <source>Trends Cell Biol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>79</fpage>
          <lpage>85</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Park1">
        <label>29</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Park</surname>
              <given-names>JH</given-names>
            </name>
            <name name-style="western">
              <surname>Walls</surname>
              <given-names>JE</given-names>
            </name>
            <name name-style="western">
              <surname>Galvez</surname>
              <given-names>JJ</given-names>
            </name>
            <name name-style="western">
              <surname>Kim</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Abate-Shen</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prostatic intraepithelial neoplasia in genetically engineered mice.</article-title>
          <source>Am J Pathol</source>
          <year>2002</year>
          <volume>161</volume>
          <fpage>727</fpage>
          <lpage>735</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Podsypanina1">
        <label>30</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Podsypanina</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Ellenson</surname>
              <given-names>LH</given-names>
            </name>
            <name name-style="western">
              <surname>Nemes</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Gu</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Tamura</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation of <italic>Pten/Mmac1</italic> in mice causes neoplasia in
            multiple organ systems.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>1563</fpage>
          <lpage>1568</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Shin1">
        <label>31</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Shin</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Yakes</surname>
              <given-names>FM</given-names>
            </name>
            <name name-style="western">
              <surname>Rojo</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Shin</surname>
              <given-names>NY</given-names>
            </name>
            <name name-style="western">
              <surname>Bakin</surname>
              <given-names>AV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at
            threonine 157 and modulation of its cellular localization.</article-title>
          <source>Nat Med</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>1145</fpage>
          <lpage>1152</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Stambolic1">
        <label>32</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Stambolic</surname>
              <given-names>V</given-names>
            </name>
            <name name-style="western">
              <surname>Suzuki</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>de la Pompa</surname>
              <given-names>JL</given-names>
            </name>
            <name name-style="western">
              <surname>Brothers</surname>
              <given-names>GM</given-names>
            </name>
            <name name-style="western">
              <surname>Mirtsos</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Negative regulation of PKB/Akt-dependent cell survival by the tumor
            suppressor <italic>PTEN</italic>.</article-title>
          <source>Cell</source>
          <year>1998</year>
          <volume>95</volume>
          <fpage>29</fpage>
          <lpage>39</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Suzuki1">
        <label>33</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Suzuki</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>de la Pompa</surname>
              <given-names>JL</given-names>
            </name>
            <name name-style="western">
              <surname>Stambolic</surname>
              <given-names>V</given-names>
            </name>
            <name name-style="western">
              <surname>Elia</surname>
              <given-names>AJ</given-names>
            </name>
            <name name-style="western">
              <surname>Sasaki</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High cancer susceptibility and embryonic lethality associated with mutation
            of the <italic>PTEN</italic> tumor suppressor gene in mice.</article-title>
          <source>Curr Biol</source>
          <year>1998</year>
          <volume>8</volume>
          <fpage>1169</fpage>
          <lpage>1178</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Viglietto1">
        <label>34</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Viglietto</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Motti</surname>
              <given-names>ML</given-names>
            </name>
            <name name-style="western">
              <surname>Bruni</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Melillo</surname>
              <given-names>RM</given-names>
            </name>
            <name name-style="western">
              <surname>D'Alessio</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase
            inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.</article-title>
          <source>Nat Med</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>1136</fpage>
          <lpage>1144</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Vivanco1">
        <label>35</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Vivanco</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Sawyers</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>The phosphatidylinositol 3-kinase AKT pathway in human cancer.</article-title>
          <source>Nat Rev Cancer</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>489</fpage>
          <lpage>501</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Whang1">
        <label>36</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Whang</surname>
              <given-names>YE</given-names>
            </name>
            <name name-style="western">
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name name-style="western">
              <surname>Suzuki</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Reiters</surname>
              <given-names>RE</given-names>
            </name>
            <name name-style="western">
              <surname>Tran</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inactivation of the tumor suppressor <italic>Pten/MMAC1</italic> in
            advanced human prostate cancer through loss of expression.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1998</year>
          <volume>95</volume>
          <fpage>5246</fpage>
          <lpage>5250</lpage>
        </nlm-citation>
      </ref>
      <ref id="pbio.0000059-Wu1">
        <label>37</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name name-style="western">
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Huang</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Powell</surname>
              <given-names>WC</given-names>
            </name>
            <name name-style="western">
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Generation of a prostate epithelial cell-specific <italic>Cre</italic>
            transgenic mouse model for tissue-specific gene ablation.</article-title>
          <source>Mech Dev</source>
          <year>2001</year>
          <volume>101</volume>
          <fpage>61</fpage>
          <lpage>69</lpage>
        </nlm-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>AP</term>
          <def>
            <p>anterior prostate</p>
          </def>
        </def-item>
        <def-item>
          <term>BPH</term>
          <def>
            <p>benign prostatic hyperplasia</p>
          </def>
        </def-item>
        <def-item>
          <term>CaP</term>
          <def>
            <p>cancer of the prostate</p>
          </def>
        </def-item>
        <def-item>
          <term>ES</term>
          <def>
            <p>embryonic stem</p>
          </def>
        </def-item>
        <def-item>
          <term>H&amp;E</term>
          <def>
            <p>hematoxylin and eosin</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>HPRT</italic>
          </term>
          <def>
            <p>hypoxanthine phosphoribosyltransferase</p>
          </def>
        </def-item>
        <def-item>
          <term>IHC</term>
          <def>
            <p>immunohistochemistry</p>
          </def>
        </def-item>
        <def-item>
          <term>mAb</term>
          <def>
            <p>monoclonal antibody</p>
          </def>
        </def-item>
        <def-item>
          <term>MEF</term>
          <def>
            <p>mouse embryonic fibroblast</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>Neo</term>
          <def>
            <p>neomycin</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>PB</italic>
          </term>
          <def>
            <p>
              <italic>Probasin</italic>
            </p>
          </def>
        </def-item>
        <def-item>
          <term>PBMC</term>
          <def>
            <p>peripheral blood mononuclear cell</p>
          </def>
        </def-item>
        <def-item>
          <term>PI3K</term>
          <def>
            <p>phosphoinositide 3-kinase</p>
          </def>
        </def-item>
        <def-item>
          <term>PIN</term>
          <def>
            <p>prostatic intraepithelial neoplasia</p>
          </def>
        </def-item>
        <def-item>
          <term>PIP3</term>
          <def>
            <p>phosphatidylinositol 3,4,5-trisphosphate</p>
          </def>
        </def-item>
        <def-item>
          <term>PTEN</term>
          <def>
            <p>phosphatase and tensin homolog deleted on chromosome 10</p>
          </def>
        </def-item>
        <def-item>
          <term>RNAi</term>
          <def>
            <p>RNA interference</p>
          </def>
        </def-item>
        <def-item>
          <term>siRNA</term>
          <def>
            <p>small interfering RNA</p>
          </def>
        </def-item>
        <def-item>
          <term>WB</term>
          <def>
            <p>Western blot</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>